Stevanato Group, an Italian provider of containment and delivery solutions for the pharmaceutical industry, filed on Monday with the SEC to raise up to $100 million.
Stevanato Group is a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. The company delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle. Stevanato Group serves more than 700 companies globally, including 41 of the top 50 pharmaceuticals and 8 of the top 10 in-vitro diagnostic companies.
The Padua, Italy-based company was founded in 1949 and booked $852 million in revenue for the 12 months ended March 31, 2021. It plans to list on the NYSE under the symbol STVN. Stevanato Group filed confidentially on March 22, 2021. Morgan Stanley, BofA Securities, Jefferies, Citi, KeyBanc Capital Markets, UBS Investment Bank, Wells Fargo Securities, and William Blair are the joint bookrunners on the deal. No pricing terms were disclosed.
